ArticleFrontiers in molecular biosciences2025
Comprehensive bioinformatics analysis of the common mechanism of atherosclerosis and atrial fibrillation: emphasizing mitochondrial metabolic disorder and immune inflammation.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Atherosclerosis (AS) and atrial fibrillation (AF) are clinically intertwined cardiovascular disorders, yet their shared pathophysiological mechanisms remain poorly understood. Mitochondrial dysfunction and immune dysregulation have been implicated separately in both diseases, but their potential crosstalk in driving comorbidity is unexplored. This study aims to uncover common molecular pathways linking AS and AF, focusing on mitochondrial metabolism and immune response, and to identify diagnostic biomarkers using integrative bioinformatics approaches. Methods: Transcriptomic datasets of AS and AF were analyzed through GO and KEGG enrichment to identify shared biological themes. WWGCNA prioritized 35 mitochondrial genes associated with both diseases. Three machine learning algorithms (LASSO, SVM, and random forest) were applied to screen hub genes, followed by validation in independent datasets. Immune infiltration and single-cell transcriptomic analyses were conducted to assess immune-microenvironment interactions and gene expression at cellular resolution. Results: GO/KEGG analyses revealed dominant enrichment in mitochondrial oxidative phosphorylation and immune-inflammatory pathways for AS and AF. WGCNA identified 35 mitochondrial hub genes, with MRPS23 and CASP8 emerging as key candidates via machine learning. MRPS23 showed significant downregulation in AS tissues and cellular heterogeneity in scRNA-seq (single-cell RNA sequencing), while both genes exhibited strong correlations with immune cell subsets in both diseases. Conclusion: This study establishes MRPS23 as a novel biomarker bridging mitochondrial dysfunction and immune dysregulation in AS and AF comorbidity. Its decline in AS suggests a potential role in mitochondrial ribosomal integrity loss driving metabolic stress, while immune-microenvironment interactions highlight its pleiotropic impacts on inflammatory cascades. These findings advance the "mitochondria-immune axis" paradigm for cardiovascular comorbidity, offering MRPS23 as a dual-disease therapeutic target. Further validation in preclinical models and clinical cohorts is needed to translate these insights into diagnostic or therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.